A 28-year-old person has had a “cold” with symptoms of fatig…

A 28-year-old person has had a “cold” with symptoms of fatigue, rhinorrhea, and nasal congestion for the past 2 days.  This morning, they also developed a mild headache in their frontal sinuses and some shortness of breath.  They took ibuprofen 200 mg x 2 tablets (400 mg total dose) already for the headache and are asking what other recommendations you have for treatment of their symptoms.  Which of the following would be the best recommendation for this person?

A manufacturer markets a new OTC analgesic in sustained rele…

A manufacturer markets a new OTC analgesic in sustained release tablet form. The product uses a foil seal over the bottle opening and a band around the bottle cap as tamper-evident features. The labeling includes a statement about these features, which is printed on the foil seal itself. Which of the following best describes the regulatory concern with this labeling practice?

A 24-year-old college student asks you for a recommendation…

A 24-year-old college student asks you for a recommendation for “cold” symptoms.  They take no prescription or OTC medications or supplements and have no medication allergies, but they do have a past medical history of a broken arm and paroxysmal tachycardia (episodic rapid heart rate that begins and ends suddenly).  Which of the following nonprescription medications would be important for this student to avoid in OTC cold products?

A 24-year-old college student asks you for a recommendation…

A 24-year-old college student asks you for a recommendation for “cold” symptoms.  They take no prescription or OTC medications or supplements and have no medication allergies, but they do have a past medical history of a broken arm and paroxysmal tachycardia (episodic rapid heart rate that begins and ends suddenly).  Which of the following nonprescription medications would be important for this student to avoid in OTC cold products?

A manufacturer markets a new OTC analgesic in sustained rele…

A manufacturer markets a new OTC analgesic in sustained release tablet form. The product uses a foil seal over the bottle opening and a band around the bottle cap as tamper-evident features. The labeling includes a statement about these features, which is printed on the foil seal itself. Which of the following best describes the regulatory concern with this labeling practice?